Legend Biotech Corporation(LEGN)Earnings, Financials & Key Ratios
LEGN•NASDAQ
Price updated Jun 19, 2026
AboutLegend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Show more
- Revenue$1.03B+64.0%
- EBITDA-$108M+61.6%
- Net Income-$297M-67.7%
- EPS (Diluted)-1.60-64.9%
- Gross Margin60.34%-3.6%
- EBITDA Margin-10.46%+76.6%
- Operating Margin-13.27%+72.6%
- Net Margin-28.85%-2.2%
- ROE-29.06%-88.1%
LEGN Key Insights
Legend Biotech Corporation (LEGN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 82 (top 18%)
- ✓Strong 5Y sales CAGR of 68.8%
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when LEGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LEGN Price & Volume
Legend Biotech Corporation (LEGN) stock price & volume — 10-year historical chart
Loading chart...
LEGN Growth Metrics
Legend Biotech Corporation (LEGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years68.83%
3 Years106.41%
TTM56.37%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-14.68%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-15.16%
Return on Capital
10 Years-27.34%
5 Years-32.76%
3 Years-21.33%
Last Year-10.96%
LEGN Recent Earnings
Legend Biotech Corporation (LEGN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 2/12 qtrs (17%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.15-650.0%
$0.02
Rev
$305M-0.5%
$307M
Q2 2026
Mar 10, 2026Metric
Actual
Est
EPS
$0.08+52.9%
$0.17
Rev
$306M-0.5%
$308M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.11+15.4%
$0.13
Rev
$272M-12.0%
$310M
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.34-54.5%
$0.22
Rev
$256M-8.0%
$278M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.15vs $0.02-650.0% | $305Mvs $307M-0.5% |
| Q2 2026 | Mar 10, 2026 | $0.08vs $0.17+52.9% | $306Mvs $308M-0.5% |
| Q4 2025 | Nov 12, 2025 | $0.11vs $0.13+15.4% | $272Mvs $310M-12.0% |
| Q3 2025 | Aug 11, 2025 | $0.34vs $0.22-54.5% | $256Mvs $278M-8.0% |
Based on last 12 quarters of dataView full earnings history →
LEGN Peer Comparison
Legend Biotech Corporation (LEGN) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 BMY | 110.25B | 54.00 | 15.65 | -0.22% | 15.01% | 38.96% | 2.55 | |
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 | |
 SRPT | 1.85B | 17.53 | -2.46 | 15.58% | 2.98% | 4.89% | 0.91 |
Compare LEGN vs Peers
Legend Biotech Corporation (LEGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LEGN Income Statement
Legend Biotech Corporation (LEGN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 23.59M | 49.13M | 61.8M | 75M | 68.83M | 117M | 285.14M | 627.24M | 1.03B | 1.14B |
Revenue Growth % | - | 108.24% | 25.78% | 21.36% | -8.23% | 70% | 143.7% | 119.97% | 64.04% | 56.37% |
Cost of Goods Sold | -96K | 0 | 0 | 0 | 0 | 65.36M | 144.21M | 234.58M | 408.1M | 512.66M |
COGS % of Revenue | -0.41% | - | - | - | - | 55.86% | 50.58% | 37.4% | 39.66% | - |
Gross Profit | 23.69M▲ 0% | 49.13M▲ 107.4% | 61.8M▲ 25.8% | 75M▲ 21.4% | 68.83M▼ 8.2% | 51.64M▼ 25.0% | 140.93M▲ 172.9% | 392.66M▲ 178.6% | 620.8M▲ 58.1% | 626.21M▲ 0% |
Gross Margin % | 100.41% | 100% | 100% | 100% | 100% | 44.14% | 49.42% | 62.6% | 60.34% | 54.99% |
Gross Profit Growth % | - | 107.4% | 25.78% | 21.36% | -8.23% | -24.97% | 172.9% | 178.62% | 58.1% | - |
Operating Expenses | 9.6M | 64.2M | 194.31M | 75M | 461.11M | 507.26M | 580.41M | 695.9M | 757.3M | 761.94M |
OpEx % of Revenue | 40.67% | 130.68% | 314.42% | 100% | 669.97% | 433.54% | 203.55% | 110.95% | 73.6% | - |
Selling, General & Admin | 1.4M | 3.93M | 32.37M | 72.7M | 149.5M | 174.05M | 200.93M | 284.26M | 341.6M | 359.27M |
SG&A % of Revenue | 5.94% | 8% | 52.38% | 96.94% | 217.22% | 148.75% | 70.47% | 45.32% | 33.2% | - |
Research & Development | 8.2M | 60.64M | 161.94M | 232.16M | 313.35M | 335.65M | 382.22M | 413.54M | 414.7M | 398.73M |
R&D % of Revenue | 34.73% | 123.41% | 262.04% | 309.55% | 455.27% | 286.87% | 134.04% | 65.93% | 40.31% | - |
Other Operating Expenses | 0 | -2K | 0 | -229.87M | -1.74M | -2.43M | -2.73M | -1.91M | 1M | 2M |
Operating Income | 13.78M▲ 0% | -1.53M▼ 111.1% | -132.51M▼ 8538.5% | 0▲ 100.0% | -392.29M▲ 0% | -455.62M▼ 16.1% | -439.49M▲ 3.5% | -303.24M▲ 31.0% | -136.5M▲ 55.0% | -135.74M▲ 0% |
Operating Margin % | 58.41% | -3.12% | -214.42% | - | -569.97% | -389.4% | -154.13% | -48.35% | -13.27% | -11.92% |
Operating Income Growth % | - | -111.13% | -8538.46% | 100% | - | -16.14% | 3.54% | 31% | 54.99% | - |
EBITDA | 14M | 149K | -129.35M | -298.16M | -378.37M | -437.23M | -419.03M | -279.88M | -107.6M | -96.43M |
EBITDA Margin % | 59.33% | 0.3% | -209.31% | -397.54% | -549.75% | -373.68% | -146.96% | -44.62% | -10.46% | -8.47% |
EBITDA Growth % | - | -98.94% | -86912.75% | -130.5% | -26.9% | -15.56% | 4.16% | 33.21% | 61.56% | 54.98% |
D&A (Non-Cash Add-back) | 217K | 1.68M | 3.16M | 9.93M | 13.92M | 18.39M | 20.45M | 23.36M | 28.9M | 39.3M |
EBIT | 13.84M | -1.53M | -132.51M | -308.09M | -406.3M | -434.93M | -498.32M | -136.52M | -261.2M | -220.37M |
Net Interest Income | 0 | 6.13M | 4.36M | -1.28M | 71K | -2.61M | 32.69M | 39.59M | 18.7M | 13.53M |
Interest Income | 1K | 6.21M | 4.58M | 2.93M | 971K | 8.18M | 54.49M | 61.2M | 40.1M | 35.39M |
Interest Expense | 0 | 82K | 223K | 4.21M | 900K | 10.8M | 21.79M | 21.61M | 21.4M | 21.86M |
Other Income/Expense | -40K | 13.46M | 5.2M | -308.29M | -14.91M | 9.9M | -80.63M | 145.11M | -146.1M | -100.83M |
Pretax Income | 13.84M▲ 0% | -1.62M▼ 111.7% | -127.32M▼ 7778.7% | -308.29M▼ 142.1% | -407.2M▼ 32.1% | -445.72M▼ 9.5% | -520.12M▼ 16.7% | -158.13M▲ 69.6% | -282.6M▼ 78.7% | -236.57M▲ 0% |
Pretax Margin % | 58.65% | -3.29% | -206.02% | -411.05% | -591.63% | -380.94% | -182.41% | -25.21% | -27.47% | -20.77% |
Income Tax | 4.47M | 1.17M | -25.73M | -41.91M | -3.61M | 625K | -1.86M | 18.89M | 14.2M | 13.61M |
Effective Tax Rate % | 32.32% | -72.28% | 20.21% | 13.6% | 0.89% | -0.14% | 0.36% | -11.95% | -5.02% | -5.75% |
Net Income | 9.37M▲ 0% | -2.78M▼ 129.7% | -101.59M▼ 3549.1% | -266.37M▼ 162.2% | -403.58M▼ 51.5% | -446.35M▼ 10.6% | -518.25M▼ 16.1% | -177.03M▲ 65.8% | -296.8M▼ 67.7% | -250.18M▲ 0% |
Net Margin % | 39.69% | -5.67% | -164.39% | -355.16% | -586.38% | -381.48% | -181.75% | -28.22% | -28.85% | -21.97% |
Net Income Growth % | - | -129.73% | -3549.07% | -162.2% | -51.51% | -10.6% | -16.11% | 65.84% | -67.66% | -14.68% |
Net Income (Continuing) | 9.37M | -2.78M | -101.59M | -266.37M | -403.58M | -446.35M | -518.25M | -177.03M | -296.8M | -250.18M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.07▲ 0% | -0.03▼ 139.2% | -1.01▼ 3533.1% | -2.57▼ 154.5% | -2.74▼ 6.6% | -2.81▼ 2.6% | -2.94▼ 4.6% | -0.97▲ 67.0% | -1.60▼ 64.9% | -1.35▲ 0% |
EPS Growth % | - | -139.21% | -3533.09% | -154.46% | -6.61% | -2.55% | -4.63% | 67.01% | -64.95% | -15.16% |
EPS (Basic) | 0.07 | -0.03 | -1.01 | -2.57 | -2.74 | -2.81 | -2.94 | -0.97 | -1.60 | - |
Diluted Shares Outstanding | 132.01M | 100.21M | 132.01M | 118.15M | 140.85M | 159.04M | 176.08M | 182.85M | 184.32M | 184.73M |
Basic Shares Outstanding | 132.01M | 100M | 132.01M | 118.15M | 140.85M | 159.04M | 176.08M | 182.85M | 184.32M | 184.73M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
LEGN Balance Sheet
Legend Biotech Corporation (LEGN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 230.9M | 326.96M | 207.1M | 593.94M | 949.85M | 1.1B | 1.5B | 1.28B | 1.25B | 1.08B |
Cash & Short-Term Investments | 2.12M | 216.18M | 159.18M | 506.07M | 882.39M | 1.03B | 1.31B | 1.12B | 948.6M | 834.63M |
Cash Only | 2.12M | 210.17M | 83.62M | 456.07M | 688.94M | 786.03M | 1.28B | 286.75M | 901.9M | 646.42M |
Short-Term Investments | 0 | 6.01M | 75.56M | 50M | 193.46M | 239.62M | 31M | 835.93M | 46.7M | 188.21M |
Accounts Receivable | 228.74M | 108.57M | 35.76M | 82.62M | 58.55M | 44.52M | 157.06M | 124.89M | 250.3M | 186.61M |
Days Sales Outstanding | 3.54K | 806.53 | 211.19 | 402.06 | 310.49 | 138.87 | 201.05 | 72.67 | 88.79 | 69.58 |
Inventory | 11K | 1.14M | 1.16M | 1.8M | 1.75M | 10.35M | 19.43M | 23.9M | 32M | 37.1M |
Days Inventory Outstanding | -41.82 | - | - | - | - | 57.82 | 49.18 | 37.19 | 28.62 | 23.83 |
Other Current Assets | 760K | 255K | 0 | 0 | 1.44M | 1.27M | 357K | 70K | 1.6M | 5M |
Total Non-Current Assets | 7.79M | 102.09M | 80.61M | 128.15M | 169.62M | 231.84M | 350.81M | 386.24M | 486.6M | 514.02M |
Property, Plant & Equipment | 2.93M | 33.13M | 80.09M | 112.11M | 142.96M | 161.67M | 189.68M | 201.59M | 402M | 452.51M |
Fixed Asset Turnover | 8.06x | 1.48x | 0.77x | 0.67x | 0.48x | 0.72x | 1.50x | 3.11x | 2.56x | 3.39x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 2K | 49K | 519K | 2.85M | 16.8M | 68.69M | 4.06M | 174.22M | 74.6M | 35M |
Long-Term Investments | -4.86M | -1.24M | 0 | 0 | 4.71M | 0 | 4.36M | 4.36M | 5M | 5M |
Other Non-Current Assets | 4.86M | 1.24M | 0 | 13.19M | 5.15M | 1.49M | 152.42M | 6.06M | 5M | 26.5M |
Total Assets | 238.69M▲ 0% | 429.05M▲ 79.7% | 287.71M▼ 32.9% | 722.09M▲ 151.0% | 1.12B▲ 55.0% | 1.33B▲ 18.9% | 1.85B▲ 38.9% | 1.67B▼ 9.7% | 1.73B▲ 3.8% | 1.6B▲ 0% |
Asset Turnover | 0.10x | 0.11x | 0.21x | 0.10x | 0.06x | 0.09x | 0.15x | 0.38x | 0.59x | 0.68x |
Asset Growth % | - | 79.75% | -32.94% | 150.98% | 55.03% | 18.89% | 38.89% | -9.65% | 3.8% | -4.7% |
Total Current Liabilities | 52.12M | 159.19M | 127.76M | 115.57M | 229.2M | 297.79M | 216.42M | 277.64M | 636.4M | 509.12M |
Accounts Payable | 4.33M | 7.32M | 9.59M | 4.91M | 7.04M | 31.69M | 20.16M | 37.19M | 81.2M | 74.3M |
Days Payables Outstanding | -16.48K | - | - | - | - | 176.98 | 51.02 | 57.87 | 72.62 | 59.33 |
Short-Term Debt | 0 | 0 | 1.03M | 1.79M | 0 | 0 | 0 | 0 | 319.1M | 266M |
Deferred Revenue (Current) | 30.21M | 40.32M | 46.29M | 55.01M | 304K | 451K | 53.01M | 47.41M | 11.3M | 74.71M |
Other Current Liabilities | 38.08M | 34.16M | 64.22M | 31.45M | 87.9M | 67M | 68K | 0 | 1M | 131.31M |
Current Ratio | 4.43x | 2.05x | 1.62x | 5.14x | 4.14x | 3.69x | 6.92x | 4.62x | 1.96x | 2.13x |
Quick Ratio | 4.43x | 2.05x | 1.61x | 5.12x | 4.14x | 3.66x | 6.83x | 4.54x | 1.91x | 2.05x |
Cash Conversion Cycle | 19.98K | - | - | - | - | 19.7 | 199.21 | 51.99 | 44.79 | 34.08 |
Total Non-Current Liabilities | 174.4M | 261.21M | 282.82M | 6.7M | 124.32M | 288.86M | 380.82M | 351.96M | 95.2M | 119.9M |
Long-Term Debt | 0 | 0 | 0 | 0 | 120.46M | 260.93M | 281.33M | 301.2M | 0 | 0 |
Capital Lease Obligations | 205K | 3.94M | 5.08M | 1.91M | 1.59M | 20.04M | 44.17M | 44.61M | 87.2M | 359.11M |
Deferred Tax Liabilities | -174.2M | -213.2M | 0 | 4.24M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | -274.52M | 396K | 233K | 56K | 0 | 8M | 7.8M |
Total Liabilities | 226.53M | 420.4M | 410.58M | 122.27M | 353.52M | 586.65M | 597.24M | 629.61M | 731.6M | 629.02M |
Total Debt | 269K | 4.32M | 6.11M | 3.7M | 122.97M | 284.53M | 328.67M | 350.6M | 413.7M | 389.31M |
Net Debt | -1.85M | -205.85M | -77.51M | -452.37M | -565.97M | -501.5M | -949.04M | 63.85M | -488.2M | -257.11M |
Debt / Equity | 0.02x | 0.50x | - | 0.01x | 0.16x | 0.38x | 0.26x | 0.34x | 0.41x | 0.40x |
Debt / EBITDA | 0.02x | 28.97x | - | - | - | - | - | - | - | -4.04x |
Net Debt / EBITDA | -0.13x | -1381.54x | - | - | - | - | - | - | - | 2.67x |
Interest Coverage | - | -18.71x | -594.23x | -73.20x | -451.44x | -40.29x | -22.87x | -6.32x | -12.21x | -10.08x |
Total Equity | 12.17M▲ 0% | 8.65M▼ 28.9% | -122.87M▼ 1520.6% | 597.77M▲ 586.5% | 765.94M▲ 28.1% | 744.31M▼ 2.8% | 1.25B▲ 68.1% | 1.04B▼ 16.8% | 1B▼ 3.7% | 967.73M▲ 0% |
Equity Growth % | - | -28.91% | -1520.61% | 586.51% | 28.13% | -2.82% | 68.12% | -16.85% | -3.69% | -28.66% |
Book Value per Share | 0.09 | 0.09 | -0.93 | 5.06 | 5.44 | 4.68 | 7.11 | 5.69 | 5.44 | 5.24 |
Total Shareholders' Equity | 12.17M | 8.65M | -122.87M | 597.77M | 765.94M | 744.31M | 1.25B | 1.04B | 1B | 967.73M |
Common Stock | 20K | 20K | 20K | 27K | 31K | 33K | 36K | 37K | 100K | 100K |
Retained Earnings | 8.47M | 5.69M | -127.28M | -116.53M | -520.11M | -966.46M | -1.48B | -1.66B | -1.96B | -2.01B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -236K | 8.63M | 485K | 5.96M | 4.86M | 14.67M | 98.92M | -68.16M | 122.2M | 199.51M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LEGN Cash Flow Statement
Legend Biotech Corporation (LEGN) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -2.38M | 307.68M | -83.06M | -223M | -198.47M | -201.28M | -393.28M | -144.03M | -100.47M | -175.24M |
Operating CF Margin % | -10.07% | 626.22% | -134.41% | -297.34% | -288.36% | -172.03% | -137.92% | -22.96% | -9.76% | - |
Operating CF Growth % | - | 13049.58% | -127% | -168.47% | 11% | -1.42% | -95.39% | 63.38% | 30.25% | -562.94% |
Net Income | 9.37M | -1.62M | -130.37M | -308.29M | -407.2M | -445.72M | -520.12M | -158.13M | -297.58M | -250.18M |
Depreciation & Amortization | 217K | 1.68M | 5.26M | 9.93M | 13.92M | 18.39M | 20.45M | 23.36M | 28.98M | 39.4M |
Stock-Based Compensation | 0 | 704K | 1.27M | 4.76M | 20.16M | 34.34M | 47.68M | 68.94M | 0 | 33.71M |
Deferred Taxes | 0 | -5.66M | -7.35M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 228.87M | -6.13M | -4.36M | 93.83M | 12.82M | 10.68M | 130.06M | -98.24M | 261.49M | 67.25M |
Working Capital Changes | -16.5M | 318.71M | 52.48M | -23.24M | 161.83M | 181.03M | -71.34M | 20.04M | -93.35M | -66.31M |
Change in Receivables | -228.06M | 207.61M | -3.77M | -45M | 24.59M | 50.32M | -98.98M | 93.75M | -132.85M | -127.35M |
Change in Inventory | -6K | -1.12M | -22K | -643K | 51K | -13.89M | -12.71M | -17.21M | -4.51M | -576.53K |
Change in Payables | 4.17M | 3.24M | 2.01M | -4.35M | 1.8M | 72.45M | -50.2M | 14.06M | 44.52M | 16.76M |
Cash from Investing | -827K | -102.26M | -58.65M | -24.17M | -194.98M | -77.09M | 92.79M | -850.54M | 711.48M | 286.2M |
Capital Expenditures | -887K | -21.02M | -39.17M | -26.25M | -42.2M | -20.93M | -20.08M | -14.11M | -67.58M | -61.12M |
CapEx % of Revenue | 3.76% | 42.78% | 63.38% | 35.01% | 61.31% | 17.89% | 7.04% | 2.25% | 6.57% | 5.37% |
Acquisitions | 60K | 20K | -460K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 55K | -75.23M | 50.52M | -23.52M | -4.91M | -16.05M | -100.52M | -54.34M | 0 | -14.98M |
Cash from Financing | 3.32M | 2.5M | 14.67M | 618.88M | 626.66M | 377.98M | 791.49M | 5.7M | -300.79K | -2.17M |
Debt Issued (Net) | -32K | -219K | -5.06M | -2.6M | -1.42M | -2.6M | -3.75M | -4.02M | 0 | -1.86M |
Equity Issued (Net) | 0 | 0 | 0 | 622.53M | 623.44M | 377.64M | 0 | 0 | 3.31M | 414.12K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 3.35M | 2.72M | 19.72M | -1.05M | 4.64M | 2.93M | 795.25M | 9.72M | -3.61M | -721.18K |
Net Change in Cash | 128K▲ 0% | 208.05M▲ 162439.8% | -126.8M▼ 160.9% | 372.32M▲ 393.6% | 233.25M▼ 37.4% | 97.09M▼ 58.4% | 491.68M▲ 406.4% | -990.96M▼ 301.5% | 615.09M▲ 162.1% | 204.65M▲ 0% |
Free Cash Flow | -3.26M▲ 0% | 286.66M▲ 8885.2% | -122.23M▼ 142.6% | -253.29M▼ 107.2% | -243.87M▲ 3.7% | -223.56M▲ 8.3% | -416M▼ 86.1% | -158.14M▲ 62.0% | -168.04M▼ 6.3% | -236.36M▲ 0% |
FCF Margin % | -13.83% | 583.44% | -197.79% | -337.72% | -354.33% | -191.07% | -145.89% | -25.21% | -16.33% | -20.75% |
FCF Growth % | - | 8885.2% | -142.64% | -107.21% | 3.72% | 8.33% | -86.08% | 61.99% | -6.26% | 13.47% |
FCF per Share | -0.02 | 2.86 | -0.93 | -2.14 | -1.73 | -1.41 | -2.36 | -0.86 | -0.91 | -1.28 |
FCF Conversion (FCF/Net Income) | -0.25x | -110.52x | 0.82x | 0.84x | 0.49x | 0.45x | 0.76x | 0.81x | 0.34x | 0.94x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LEGN Key Ratios
Legend Biotech Corporation (LEGN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -26.75% | - | -112.18% | -59.19% | -59.11% | -51.94% | -15.45% | -29.06% | -24.91% |
Return on Invested Capital (ROIC) | - | - | - | -170.38% | -154.35% | -120.93% | -32.33% | -12.65% | -11.56% |
Gross Margin | 100% | 100% | 100% | 100% | 44.14% | 49.42% | 62.6% | 60.34% | 54.99% |
Net Margin | -5.67% | -164.39% | -355.16% | -586.38% | -381.48% | -181.75% | -28.22% | -28.85% | -21.97% |
Debt / Equity | 0.50x | - | 0.01x | 0.16x | 0.38x | 0.26x | 0.34x | 0.41x | 0.40x |
Interest Coverage | -18.71x | -594.23x | -73.20x | -451.44x | -40.29x | -22.87x | -6.32x | -12.21x | -10.08x |
FCF Conversion | -110.52x | 0.82x | 0.84x | 0.49x | 0.45x | 0.76x | 0.81x | 0.34x | 0.94x |
Revenue Growth | 108.24% | 25.78% | 21.36% | -8.23% | 70% | 143.7% | 119.97% | 64.04% | 56.37% |
Related:LEGN Dividend History·LEGN Revenue History·LEGN Price History·LEGN P/E History·LEGN Financial Ratios·LEGN Institutional Holders
LEGN Frequently Asked Questions
Legend Biotech Corporation (LEGN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Legend Biotech Corporation (LEGN) reported $1.14B in revenue for fiscal year 2025. This represents a 4727% increase from $23.6M in 2017.
Legend Biotech Corporation (LEGN) grew revenue by 64.0% over the past year. This is strong growth.
Legend Biotech Corporation (LEGN) reported a net loss of $250.2M for fiscal year 2025.
Dividend & Returns
Legend Biotech Corporation (LEGN) has a return on equity (ROE) of -29.1%. Negative ROE indicates the company is unprofitable.
Legend Biotech Corporation (LEGN) had negative free cash flow of $236.4M in fiscal year 2025, likely due to heavy capital investments.